16
November

08:00 AM EST

Medicinal Chemistry
Strategy Meeting East Coast USA 2023

Reinvigorating Productivity in Pharma Biotech Through Advanced Technologies and Innovative Techniques that Interrogate Activity and Mechanisms

Le Meridien Cambridge Boston

A MEETING EXPERIENCE UNLIKE ANY OTHER

Fresh Medicinal Chemistry Insights

Tired of the same conference experience? Real discussions and genuine networking are often promised, but not always delivered. Proventa International’s R&D Strategy Meetings are designed to avoid the pitfalls of a typical conference, by providing the right environment to make those important connections through interactive roundtable discussions, exclusive networking and keynote panel debates. Join Medicinal Chemistry professionals from across the East Coast, in Boston MA, to discover new insights and take your company’s mission to the next level.

What makes our strategy meetings unique?

Roundtable Discussions

Intimate discussions led by renowned industry experts. Have your voice heard and debate alongside like-minded life science executives.

Unrivalled Networking

With senior delegation from big pharma and innovative biotech from across the East Coast, you can network with peers from different locations, all in one place.

Personalised Agenda

Choose the topics that matter to you. Reserve your place at the roundtable discussions and ensure your whole day delivers the insights you need to hear.

Solutions to your Problems

We’ve partnered with the best solution providers to solve your biggest challenges. Engage in pre-arranged, private meetings to address your specific needs and find a tangible solution.

Industry Researched Topics

We guarantee our agenda is up-to-date and mission critical because its designed by you. We speak to our extended network of senior decision makers to ensure the most important topics are discussed.

Senior Decision Makers

The entire strategy meeting is specifically tailored to the needs and challenges of senior life science professionals. Discover how your peers are dealing with the same challenges as you.

Meet Our Past Facilitators

Our panel of facilitators play a key role in shaping the agenda for the day. See who will be bringing their expertise to the table at our Medicinal Chemistry strategy meeting.

Dr. Tao Guo

SVP, Head of WuXi Chemistry – IDSU WuXi AppTec

Andreas Schoops

Head of Medicinal Chemistry WuXi AppTec

Greg Makara

CEO ChemPass

Onur Atasoylu

Director, Head of Computational Chemistry Incyte

Govinda Bhisetti

Vice President and Head of Computational Chemistry Cellarity

Matt Bursavich

Vice President, Head of Chemical Sciences Morphic Therapeutic

Heather Carlson

Vice President Chemical Data Sciences Odyssey Therapeutics

Richard Heidebrecht

Vice President and R&D Glycologix

Jason Imbriglio

Vice President, Head of Discovery Chemistry Roivant Discovery

Jason brings more than 16 years of drug discovery and medicinal chemistry expertise to <a href="https://www.roivant.com/science">Roivant Discovery</a>.
Prior to joining Roivant, Jason was a recognized leader in Merck’s global discovery chemistry department where he held positions of increasing responsibility, most recently as director of chemical biology, leading teams across all levels of preclinical discovery including target identification, target validation, lead identification and lead optimization. Jason was a founding member of Merck’s chemical biology group and a co-lead of Merck’s targeted protein degradation group. Jason contributed to the discovery of five development candidates, three INDs and was a co-inventor in the discovery of the beta-lactamase inhibitor Relebactam.
Jason has authored over 30 peer-reviewed journal articles and holds 12 patents spanning a diverse set of therapeutic areas. He holds a bachelor of arts degree in biology and bachelor of science degree in chemistry from the University of Massachusetts in Amherst, Mass. where he was a recognized Howard Hughes Undergraduate Research Fellow, a doctor of philosophy degree in organic chemistry from the University of Arizona in Tucson, Az. and a National Institute of Health Ruth L. Kirschstein National Research Service Award Postdoctoral Fellowship at Boston College in Chestnut Hill, Mass.

Kevin Kreutter

VP Drug Discovery Empress Therapeutics

Elaine Krueger

Senior Director Early Research, Head of Lead Generation Chemistry Relay Therapeutics

Stephanos Loannidis

EVP Drug Discovery Exo Therapeutics

Andrew McRiner

Vice President, Head of Drug Discovery Auron Therapeutics

Ed Olhava

Senior Vice President, Preclinical Development IFM Therapeutics

Over his nearly 20 year career in mid and early-stage biotech, Ed Olhava has invented and progressed multiple compounds through discovery and into clinical development. He has focused on discovering first-in-class small molecule modulators of new biological pathways, closely integrating medicinal chemistry, pharmacology, safety and CMC to enter clinical trials with these novel entities.
Before joining <a href="https://www.ifmthera.com/">IFM</a>, Ed was a strategic advisor at Third Rock Ventures, where he developed the strategic and operational plans for the drug discovery groups of two Third Rock seed companies, both of which were successfully funded and launched. Prior to Third Rock, he was a founding scientist at Epizyme, joining the company as the first medicinal chemist. He started the medicinal chemistry group and invented Epizyme’s first clinical compound and the first clinical histone methyltransferase inhibitor, EPZ-5676, leading activities from hit finding to filing the Investigational New Drug application. Before joining Epizyme, Ed began his medicinal chemistry career at Millennium Pharmaceuticals, where he co-invented NINLARO, approved in 2015 for the treatment of multiple myeloma, and MLN-4924.
Ed obtained his Ph.D. in synthetic organic chemistry from Harvard University and B.S. in chemistry from Stanford University. He is co-author/inventor on more than 40 papers and patents.

Lewis Pennington

Senior Director. Head of Platform Chemistry Kymera Therapeutics

Nisha Perez

Senior Director, Head of DMPK ROME Therapeutics

Jennifer Petter

Founder & CSO Arrakis Therapeutics

Daniel J. Price

Executive Director, Head of Computational Chemistry Nimbus Therapeutics

Dr. Daniel Price is Executive Director and Head of Computational Chemistry at Nimbus Therapeutics. Before joining Nimbus, he a Senior Director in Computational Sciences at GlaxoSmithKline, where he led a small team of computational chemists, chemoinformaticians and data scientists operating across diverse areas of structure- and ligand-based drug design, high-content screening analytics, predictive ADME, predictive synthesis, and chemogenomics. He has led drug discovery programs, contributed to 4 clinical candidates, led the development of GSK’s first-generation R&D “data lake”, and authored/co-authored 25 publications. Dr. Price received his undergraduate degree in chemical engineering from University of Colorado at Boulder followed by his Ph.D. in Molecular Biophysics & Biochemistry from Yale University with Prof. Bill Jorgensen. He completed an NIH postdoctoral fellowship with Prof. Charlie Brooks, III at The Scripps Research Institute prior to joining GSK.

Dominic Reynolds

Senior Vice President, Head of Drug Discovery Remix Therapeutics

Atli Thorarensen

Vice President, Head of Chemistry Cellarity

Aimee Usera

Vice President Chemistry Odyssey Therapeutics

See the full agenda and facilitator line-up Download the strategy meeting brochure for full details

DOWNLOAD THE BROCHURE

Who Should Attend the Event?

Chief Executive Officers

Executive Vice Presidents

Vice Presidents

Executive Directors

Directors

Global Heads

Responsible For:

Medicinal Chemist

Computational Chemist

Translational

Chemist/Biology

In-Silico/In-vivo/In-vitro Chemist/Biologist

Chemical Biology

Molecular Chemist/Biologist

Hit and Lead Chemist

Small/Large Molecules Chemist

Drug Discovery or Drug Development

See Which Topics Are Discussed at the Strategy Meeting

08:30 – 09:00

Target Mediated Drug Disposition (TMDD): Addressing Pharmacokinetic And PK/PD Interactions To Establish Potency Of Compound Prior To Clinical Phase

09:00 – 10:00

Roundtable Tracks

Revolutionizing Drug Discovery Through AI/ML Technology To Significantly Reduce The Issues In Early Phase Discove An Exploration For Fragment-Based Drug Discovery: Discussing How To Effectively Navigate Fragment-Based Drug Discovery Method Innovative Approaches To Early Drug Discovery Through Novel Chemical Modalities Exploring The Ability Of Small Molecules In Modulating The Protein-Protein Interactions To Further Widen The Understanding About The Promising Targets For Drug Discovery The Art Of The Chemical Probe: Addressing The Limitations And Opportunities Of Chemical Probes For Early Drug Discovery Advancing An Integrated Drug Discovery Approach Through Innovations In Drug Discovery Services To Attain A More Efficient And Potent Drug Development

10:40 – 11:00

11:00 – 12:00

Roundtable Tracks

Leveraging Artificial Intelligence To Rapidly Predict Protein Attachment To Accelerate The Development Of New Drugs Taking Advantage of Polymer Structural Properties To Improve The Current Drug Delivery System The Principles, Techniques, and Applications Of Proteomics In Drug Development System Deubiquitinase-Targeting Chimeras (DUBTACs): Expanding And Assessing The Scope And Challenges Of Targeted Protein Stabilizer To Prevent The Destruction And Stabilizing The Protein Levels Of Ubiquitin Chains From Actively Degraded Proteins Analyzing The Applications And Impact Of Nuclear Magnetic Resonance In Lead Identification, Optimization, And Drug Compound Aggregation Novel Drug Modality Update: Current Advances In Antibody-Drug Conjugates As Therapeutic

Reasons To Attend the Strategy Meeting

Discussions on the advancements in targeted protein degradation andrnpushing past its boundaries.

Leveraging Artificial Intelligence and Machine Learning in accelerating therndevelopment of new drugs

Discuss approaches to further understand the interactions of undruggablerntargets and different Protein Degraders such as PROTACs, Molecular Glues,rnetc

Focusing on advancing interrogative techniques to improve the Drug Delivery System/Discovery: Modified mRNA, Nanoparticle-Mediated siRNA, Antibody-Drug Conjugates, and more

Press play to hear what your colleagues had to say…

Become an official strategy meeting partner Whatever your business needs, we can help. Get in touch for partnering opportunities

I’D LIKE TO PARTNER

Here To Help

Want to know more? Interested in sponsoring the event? Need help registering your team?rnrnJust get in touch and a member of the team will be happy to help.

Quick Links

Want to find out more?

Find out more details about our Strategy Meetings and other news and events.

Europe

USA East

USA West

Webinars

Dinners & Spotlights

R&D

R&D Boston

Drug Discovery Biology Strategy Meeting East Coast November 2023

Medicinal Chemistry Strategy Meeting East Coast USA 2023

<img decoding="async" src="https://proventainternational.com/wp-content/uploads/2020/12/location.png" >Le Meridien Cambridge Boston

Fresh Medicinal Chemistry Insights

What makes our strategy meetings unique?

Roundtable Discussions

Unrivalled Networking

Personalised Agenda

Solutions to your Problems

Industry Researched Topics

Senior Decision Makers

Meet Our Past Facilitators

Dr. Tao Guo

Andreas Schoops

Greg Makara

Onur Atasoylu

Govinda Bhisetti

Matt Bursavich

Heather Carlson

Richard Heidebrecht

Jason Imbriglio

Kevin Kreutter

Elaine Krueger

Stephanos Loannidis

Andrew McRiner

Ed Olhava

Lewis Pennington

Nisha Perez

Jennifer Petter

Daniel J. Price

Dominic Reynolds

Atli Thorarensen

Aimee Usera

Who Should Attend the Event?

Chief Executive Officers

Executive Vice Presidents

Vice Presidents

Executive Directors

Directors

Global Heads

Responsible For:

Medicinal Chemist

Computational Chemist

Translational

Chemist/Biology

In-Silico/In-vivo/In-vitro Chemist/Biologist

Chemical Biology

Molecular Chemist/Biologist

Hit and Lead Chemist

Small/Large Molecules Chemist

Drug Discovery or Drug Development

See Which Topics Are Discussed at the Strategy Meeting

REGISTRATION AND WELCOME

OPENING KEYNOTE PRESENTATION

Target Mediated Drug Disposition (TMDD): Addressing Pharmacokinetic And PK/PD Interactions To Establish Potency Of Compound Prior To Clinical Phase

Roundtable

Roundtable Tracks

NETWORKING / 1-1 MEETINGS

NETWORKING / 1-1 MEETINGS

NETWORKING / 1-1 MEETINGS

Roundtable

Roundtable Tracks

NETWORKING LUNCH

Reasons To Attend the Strategy Meeting

Our Past Leader Sponsor

Our Past Co-Hosts

Press play to hear what your colleagues had to say…

Here To Help

Want to find out more?

Select days you wish to attend You can add multiple days

Pass includes:

VAT Excluded

Select days you wish to attend You can add multiple days

Medicinal Chemistry
Strategy Meeting East Coast USA 2023

Le Meridien Cambridge Boston